Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trials in Qingdao, Shandong
3 recruitingQingdao, Shandong, China
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited132 enrolled30 locationsNCT07327229
Recruiting
Phase 3
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.560 enrolled68 locationsNCT07284134
Recruiting
Phase 2
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University59 enrolled7 locationsNCT05585580